{
  "title": "Artificial intelligence system predicts consequences of gene modifications",
  "story": [
    {
      "type": "paragraph",
      "id": "57a2392e83aa50d5",
      "text": "[https://medicalxpress.com/news/2023-05-artificial-intelligence-consequences-gene-modifications.html https://medicalxpress.com/news/2023-05-artificial-intelligence-consequences-gene-modifications.html]"
    },
    {
      "type": "markdown",
      "id": "370e74a8ce0d286b",
      "text": "&quot;The new model, dubbed Geneformer, learns from massive amounts of data on gene interactions from a broad range of human tissues and transfers this knowledge to make predictions about how things might go wrong in disease.&quot;"
    },
    {
      "type": "paragraph",
      "id": "fd13a1b511e287c4",
      "text": "Would commercial or academic life science organizations apply this capability to reduce human trial expenses for certain genetically engineered medicines or treatments, like CAR T-cells used to treat leukemia? Would prescription drug prices decline as a result?"
    },
    {
      "type": "markdown",
      "id": "cdfcfdee886851aa",
      "text": "Source: medicalxpress.com via [https://catless.ncl.ac.uk/Risks/33/72/#subj17.1 The Risks Digest]"
    }
  ],
  "journal": [
    {
      "type": "create",
      "date": 1685930465000,
      "item": {
        "title": "Artificial intelligence system predicts consequences of gene modifications",
        "story": [
          {
            "type": "paragraph",
            "id": "57a2392e83aa50d5",
            "text": "[https://medicalxpress.com/news/2023-05-artificial-intelligence-consequences-gene-modifications.html https://medicalxpress.com/news/2023-05-artificial-intelligence-consequences-gene-modifications.html]"
          },
          {
            "type": "markdown",
            "id": "370e74a8ce0d286b",
            "text": "&quot;The new model, dubbed Geneformer, learns from massive amounts of data on gene interactions from a broad range of human tissues and transfers this knowledge to make predictions about how things might go wrong in disease.&quot;"
          },
          {
            "type": "paragraph",
            "id": "fd13a1b511e287c4",
            "text": "Would commercial or academic life science organizations apply this capability to reduce human trial expenses for certain genetically engineered medicines or treatments, like CAR T-cells used to treat leukemia? Would prescription drug prices decline as a result?"
          },
          {
            "type": "markdown",
            "id": "cdfcfdee886851aa",
            "text": "Source: medicalxpress.com via [https://catless.ncl.ac.uk/Risks/33/72/#subj17.1 The Risks Digest]"
          }
        ]
      }
    },
    {
      "type": "fork",
      "site": "risks.rodwell.me",
      "date": 1686124026125
    }
  ]
}